INDP news

Indaptus Therapeutics has agreed to extend the outside date for certain stock purchase agreements from Sept. 29 to Oct. 16, 2026, and may defer closing under coordinated conditions. Market relevance relates to the delayed funding and potential execution of capital raising activities.

Indaptus Therapeutics amended its at-market sales agreement with H.C. Wainwright & Co. for future common stock offerings, replacing its previous nearly four-year-old agreement.

Indaptus Therapeutics entered into a definitive agreement to sell up to 20 million common shares at $0.60 per share, generating approximately $12 million. This private placement will bolster the company's liquidity under existing securities exemptions.